Whitebox Advisors’s Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share IBER.WS Stock Holding History
Bought
Maintained
Sold
Other funds holding IBER.WS
Whitebox Advisors's IBER.WS Position: Q1 2023 in Review
Whitebox Advisors sold out of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) in Q1 2023, closing a stake of 34,500 shares — an estimated $614 sold.
Whitebox Advisors first reported a position in IBER.WS in Q4 2021 and held it in 5 quarters. The position peaked at $20K in Q4 2021. 1 fund tracked by Wall St. Rank holds IBER.WS as of Q1 2023.
- Whitebox Advisors reported no remaining Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position as of Q1 2023 after selling out during the quarter.
- Whitebox Advisors sold 34,500 Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share shares in Q1 2023, an estimated $614.
- Whitebox Advisors first reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in Q4 2021 and held it in 5 quarters.
- Whitebox Advisors's Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position peaked at $20K in Q4 2021.
- 1 fund tracked by Wall St. Rank held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share as of Q1 2023.
Based on Whitebox Advisors's 13F filing for Q1 2023, filed 15 May 2023.